Sunday, February 1, 2015

Testing for EGFR mutations, ALK rearrangements is cost-effective in NSCLC.

Multiplexed genetic screening for epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer setting in the United States, researchers report.







from Top Health News — ScienceDaily http://bit.ly/1CQapSG via Naturally Increase Breast Size At Home

from Tumblr http://bit.ly/1BNQJuK

No comments:

Post a Comment